These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 7946002)

  • 21. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carvedilol--A new nonselective beta blocker.
    Forrest E; Stanley A; Hayes P
    Hepatology; 2000 Mar; 31(3):809-11. PubMed ID: 10722317
    [No Abstract]   [Full Text] [Related]  

  • 23. Carvedilol: a third-generation β-blocker should be a first-choice β-blocker.
    DiNicolantonio JJ; Hackam DG
    Expert Rev Cardiovasc Ther; 2012 Jan; 10(1):13-25. PubMed ID: 22149523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
    Willette RN; Mitchell MP; Ohlstein EH; Lukas MA; Ruffolo RR
    Pharmacology; 1998 Jan; 56(1):30-6. PubMed ID: 9467185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
    Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
    Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability of carvedilol in heart failure: clinical trials experience.
    Krum H
    Am J Cardiol; 2004 May; 93(9A):58B-63B. PubMed ID: 15144940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Betablockers: old concept in a modern approach.
    Hansson BG
    Scand Cardiovasc J Suppl; 1998; 47():57-9. PubMed ID: 9540134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of carvedilol controlled-release in cardiovascular disease.
    Fonarow GC
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile.
    Bakris GL; Tarka EA; Waterhouse B; Goulding MR; Madan A; Anderson KM; St John Sutton M; Miller AB; Reichek N
    Am J Cardiol; 2006 Oct; 98(7A):46L-52L. PubMed ID: 17023232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life?
    Fowler MB
    Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carvedilol.
    Frishman WH
    N Engl J Med; 1998 Dec; 339(24):1759-65. PubMed ID: 9845712
    [No Abstract]   [Full Text] [Related]  

  • 33. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stevens-Johnson syndrome associated with carvedilol therapy.
    Kowalski BJ; Cody RJ
    Am J Cardiol; 1997 Sep; 80(5):669-70. PubMed ID: 9295009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of carvedilol on the serum lipid profile.
    Sharp RP; Sirajuddin R; Sharief IM
    Ann Pharmacother; 2008 Apr; 42(4):564-71. PubMed ID: 18364407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of alpha- and beta-adrenoceptor blockade in antihypertensive treatment.
    van Zwieten PA
    Clin Investig; 1992; 70 Suppl 1():S7-12. PubMed ID: 1350488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.
    Eggertsen R; Andrén L; Sivertsson R; Hansson L
    Eur J Clin Pharmacol; 1984; 27(1):19-22. PubMed ID: 6149128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.
    Tarantini L; Cioffi G; Opasich C; Di Lenarda A; Pulignano G; Del Sindaco D; De Feo S; Stefenelli C; Russo P; Catania G
    Ital Heart J; 2004 Jun; 5(6):441-9. PubMed ID: 15320569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with type 2 diabetes mellitus.
    Fardoun RZ
    Pharmacotherapy; 2006 Oct; 26(10):1491-500. PubMed ID: 16999659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Value of beta-blocker therapy in treatment of coronary heart disease and sudden cardiac death with special reference to carvedilol].
    Zehender M; Just H
    Z Kardiol; 1996; 85 Suppl 7():23-9. PubMed ID: 9082680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.